Literature DB >> 15876874

p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners.

Helen Rizos1, Sarah Woodruff, Richard F Kefford.   

Abstract

The p14ARF tumour suppressor regulates a series of cell cycle regulatory proteins to promote cell cycle arrest in response to abnormal hyperproliferative growth stimuli. p14ARF alterations are common in human cancers and, when inherited, confer susceptibility to cutaneous melanoma. We now propose that the mechanism of p14ARF action may involve the covalent modification of its binding partners with the small ubiquitin-related protein SUMO-1. In particular, we demonstrate that p14ARF interacts with the SUMO E2 conjugating enzyme, Ubc9 and enhances the sumoylation of its binding partners, hdm2, E2F-1, HIF-1alpha, TBP-1 and p120E4F. Furthermore, p14ARF-induced sumoylation is abrogated by a subset of melanoma-associated p14ARF mutations. These results provide a mechanism for p14ARF action through a common modification of diverse binding partners.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876874     DOI: 10.4161/cc.4.4.1597

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  miR-34a is essential for p19(Arf)-driven cell cycle arrest.

Authors:  Nida Iqbal; Jie Mei; Jing Liu; Stephen X Skapek
Journal:  Cell Cycle       Date:  2014-01-08       Impact factor: 4.534

2.  P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3.

Authors:  Abdessamad Zerrouqi; Beata Pyrzynska; Maria Febbraio; Daniel J Brat; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

3.  MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity.

Authors:  Maren H Stindt; Stephanie Carter; Arnaud M Vigneron; Kevin M Ryan; Karen H Vousden
Journal:  Cell Cycle       Date:  2011-09-15       Impact factor: 4.534

4.  Isolation and characterization of mammalian cells expressing the Arf promoter during eye development.

Authors:  Nida S Iqbal; Lin Xu; Caitlin C Devitt; Stephen X Skapek
Journal:  Biotechniques       Date:  2014-05-01       Impact factor: 1.993

5.  PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Authors:  Lisa Ivanschitz; Yuki Takahashi; Florence Jollivet; Olivier Ayrault; Morgane Le Bras; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

6.  PTEN regulation by Akt-EGR1-ARF-PTEN axis.

Authors:  Jianxiu Yu; Sharon S Zhang; Kan Saito; Scott Williams; Yutaka Arimura; Yuliang Ma; Yuehai Ke; Veronique Baron; Dan Mercola; Gen-Sheng Feng; Eileen Adamson; Tomas Mustelin
Journal:  EMBO J       Date:  2008-12-04       Impact factor: 11.598

7.  p19(Arf) limits primary vitreous cell proliferation driven by PDGF-B.

Authors:  Nida S Iqbal; Caitlin C Devitt; Caroline Y Sung; Stephen X Skapek
Journal:  Exp Eye Res       Date:  2016-01-08       Impact factor: 3.467

Review 8.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

9.  Multiple domains in the 50 kDa form of E4F1 regulate promoter-specific repression and E1A trans-activation.

Authors:  Robert J Rooney
Journal:  Gene       Date:  2020-06-11       Impact factor: 3.688

Review 10.  A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics.

Authors:  Ellen Van Damme; Kris Laukens; Thanh Hai Dang; Xaveer Van Ostade
Journal:  Int J Biol Sci       Date:  2010-01-12       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.